AzTrials
AzTrials

Autism Spectrum DisordersEYENCT02573428

Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder

An observational study of Autism Spectrum Disorders, run by The Cleveland Clinic at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary purpose of the present study is to evaluate the diagnostic validity of eye tracking measurements acquired during viewing of socially-relevant stimuli in predicting ASD diagnosis. Read more about this study

Who is it for?
Ages 18 months to 18 yearsHealthy volunteers can take part
Conditions the study is for
Autism Spectrum Disorders
How many people
389 participants
Where
1 siteUnited States
Study dates
Jun 2015to Dec 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 months to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: ASD and Non-ASD participants will be recruited following their evaluations in the Center for Autism diagnostic clinics as well as from the Social Practice and Instruction Enhances Socialization (SPIES) program both of which are part of the Cleveland Clinic Center for Autism.

Who may be able to join

  • Clinical diagnosis of Autism Spectrum Disorder (299.0) following evaluation in Cleveland Clinic Center for Autism Diagnostic Clinic, or a clinical diagnosis of another developmental or psychiatric disorder, or have no specific developmental or psychiatric diagnosis.
  • Age 1.5 to 18 years at time of consent.

Who cannot join

  • Individuals whom, with corrective lenses are still legally blind.
  • Individuals whom, it is determined at the discretion of hte Primary Investigator, after consultation with the evaluating psychologist in the Center for Autism Diagnostic Clinic, are not able to sufficiently attend to the stimulus presentation or have substantial challenging behaviors that would prohibit participation.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cleveland Clinic Center for Autism

    Cleveland, Ohio, 44104

Other trials in United States

About this study

Official title: Evaluating the Validity of an Eye Gaze Tracking Assessment Tool in Identifying Autism Spectrum Disorder

The primary purpose of the present study is to evaluate the diagnostic validity of eye tracking measurements acquired during viewing of socially-relevant stimuli in predicting ASD diagnosis. The secondary purpose was to explore the potential prognostic value of eye tracking measures through cross-sectional associations with non-verbal cognitive ability.

Deficits in eye gaze are a hallmark sign of autism. A large and growing body of research supports the ability of eye-tracking based measurements to sensitively discriminate individuals with ASD and healthy participants. These investigations have identified that the core deficit in autism as disruption of social attention, reflecting an inability to appropriately engage and track socially- and emotionally-relevant aspects of the visual world. Thus, eye gaze tracking, acquired during viewing of socially-relevant stimuli, may be a useful approach to identifying objective markers of ASD. Eye tracking also carries the advantages of being less intrusive and expensive than MRI and genetic testing and specifically focuses on the core neurobehavioral characteristics of ASD - abnormalities in social attention.

After diagnosis of ASD, key clinical tasks in young children involve determining an accurate prognosis and tracking the progress of early interventions. Currently, the only prognostic indicators are clinical observations (subjective and expensive) and non-verbal cognitive ability testing (difficult to acquire, time-consuming, unavailable in many settings). Recently, eye gaze tracking was found to predict functional outcomes. Thus, in addition to being an objective marker for ASD, eye tracking measurements have potential to be useful for predicting cognitive and functional outcomes. Similarly, the only available methods for tracking treatment progress are parental reports (highly subjective), clinical observations (subjective and expensive), and cognitive measurements (expensive and unavailable in many settings. This study will evaluate, using cross-section data, the potential for eye tracking data to serve as a proxy for non-verbal cognitive ability scores in determining prognosis for ASD-affected children. Additionally, this study will evaluate the test re-test reliability of eye tracking parameters that can potentially be used to track treatment progress.

Read the detailed description

The current study will occur in four phases: pilot testing, development, validation, and re-test. In each phase, participants will view a visual attention stimulus with social elements (social attention paradigm) while eye tracking measurements are remotely acquired. The visual attention paradigm will be refined in the pilot testing but will remain the same for development, validation, and re-test phases. The entire process, including calibration and viewing of the visual paradigm, will take about 15 minutes. The text below describes each phase in detail and the reviews specific methodology for the social attention paradigm and eye tracking procedures.

  1. Pilot Phase. Pilot testing of the social attention paradigm used to elicit eye gaze measurements to ensure they are sufficiently engaging across the ages of children participating. The visual attention paradigm during this phase is expected to be 10-12 minutes. This phase will also be used to determine optimal strategies for maintaining attention throughout the testing period. Initial data may also provide some insights into the most discriminating stimulus elements to include in future phases. Investigators anticipate recruiting approximately 10 ASD and 10 non-ASD participants in this phase. The pilot phase is expected to require 2.5 months of recruitment and 0.5 months of data reduction and analysis.
  2. Development Phase. Once pilot testing is completed, 30 ASD-affected and 30 non-ASD children ages 1.5 to 18 will be recruited. Each child will complete the social attention paradigm while their eye gaze is remotely tracked. Eye gaze data is then scored for more than 100 parameters and these scores are entered into a database that includes diagnostic and cognitive information about each participant. The eye tracking data is then analyzed to create the diagnostic and prognostic algorithms that will refine the system's diagnostic sensitivity and specificity in the ASD population. The development period will require 6 months of data collection, followed by 3 months of scoring and algorithm computation.
  3. Validation Phase. Collection of the validation sample will include 60 ASD-affected and 60 non-ASD affected children ages 1.5-18. The validation phase will use the same visual social attention paradigm and methods used in the development sample. The validation period will overlap algorithm development and require 8 months of data collection and 1 month of analysis.
  4. Re-Test Phase. Participants in the re-test phase will include 30 ASD and 30 non-ASD children recruited in the first half of the validation phase. These participants will be explained in the validation phase that investigators will be re-recruiting them for the re-test phase approximately 3-6 months following their initial testing during the validation phase.

The target sample size varies depending on the phase of the study. Below are the target sample sizes for each phase:

Pilot Phase = 10 ASD and 10 Non-ASD Development Phase = 30 ASD and 30 Non-ASD Validation Phase = 60 ASD and 60 Non-ASD Re-Test Phase = 30 ASD and 30 Non-ASD (from the validation phase) The study population is individuals with autism spectrum disorder, or a clinical diagnosis of another developmental or psychiatric disorder (developmental/psychiatric controls), or have no specific developmental or psychiatric diagnosis (healthy controls), ages 1.5 (18 months) to 18 (120 months) at time of consent.

Eye gaze data will be collected using a remote eye tracker from Sensori-motoric instruments (SMI). Remote eye tracking offers minimal invasiveness to the viewer's field of view and collects time-stamped, 3D eye position, and binocular gaze and pupil data at a sampling rate of 120 Hz. Eye gaze capture is automatically calibrated to 2/5/9 points and provides position accuracy to 0.5° at a 60cm viewing distance. Gaze tracking data, screen recordings, user events, and gaze position will be recorded simultaneously. Data will be analyzed with emphasis on areas-of- interest and dwell time on specific targets on a second-by-second basis. Examples of the types of measures captured include: dwell time to any area of the stimulus, dwell time to the face and non-face regions of a human form on the video, fixation shifts between stimuli.

Additional tests and demographic data will be collected from standard of care autism diagnostic and behavioral health diagnostic appointments that can be found in the medical record.

Pilot Analyses. In the pilot phase, investigators will compute the effect size (Cohen's d) between ASD and non-ASD participants for each of the eye gaze parameters acquired for each of the individual stimuli in the social attention paradigm. Stimulus elements eliciting the largest discrimination between ASD and non-ASD patients will be retained in the development phase.

ASD Diagnostic Algorithm Analyses. In the development phase, all of the eye gaze measurements acquired from the social attention paradigm will be included as predictor variables in a random forest analysis. This analysis permits evaluation of the discriminative ability of a large number of variables in data sets with a modest number of cases. The variables with highest importance scores, indicating good diagnostic discrimination, will be entered into a logistic regression analysis with ASD diagnostic status (ASD vs. non-ASD) as the dichotomous dependent variable. Significant predictors will be retained and coefficients from the retained predictors will serve as the diagnostic algorithm.

The diagnostic algorithm scores will then be submitted to Receiver Operating Characteristic (ROC) curve analyses to provide detailed evaluation of sensitivity and specificity of the algorithm in the detection of ASD. Areas under the curve of >.90 are expected, indicating strong diagnostic validity.

Prognostic Algorithm Analyses. To identify a prognostic algorithm, a similar process will be conducted with all the available eye tracking measurements as predictors and non-verbal cognitive ability scores (dichotomized at <70 and 70 and above) as the dependent variable in random forest analyses. Non-verbal cognitive ability scores will be dichotomized based on previous data suggesting that individuals with ASD and intellectual disability show worse outcome. The predictor variables with highest importance, indicating good diagnostic discrimination, will then be entered into a logistic regression analysis with non-verbal cognitive ability (<70, >=70) as the dichotomous dependent variable. Significant predictors will be retained and coefficients from the retained predictors will serve as the prognostic algorithm. The prognostic algorithm scores will then be submitted to Receiver Operating Characteristic (ROC) curve analyses to provide detailed evaluation of sensitivity and specificity of the algorithm in the detection of non-verbal cognitive disability. Areas under the curve of >.80 are expected, indicating good validity in predicting cognitive disability. Non-verbal cognitive ability will be the primary focus of these analyses because of its documented relationship with outcome in individuals with autism. However, similar analyses will be computed for verbal cognitive ability and adaptive function scores. Investigators will also conduct the above analyses using continuous measurements as dichotomization may unnecessarily deflate validity.

Treatment Tracking Algorithm Analyses. To identify a treatment tracking algorithm, investigators will simply combine the eye tracking measurements identified in the diagnostic and prognostic algorithm into a single treatment tracking algorithm. To evaluate test re-test reliability of these measurements investigators will use intra-class correlation coefficients (model 2 - absolute agreement).

Keywords
Autism Spectrum Disorder, Eye Gaze, Remote Eye Gaze Tracking, Autism
Medical subject headings
Autism Spectrum Disorder, Autistic Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02573428
Study groupRoleWhat they receive
Autism Spectrum DisorderIndividuals who receive a clinical diagnosis of Autism Spectrum Disorder
Developmental/Psychiatric ControlsIndividuals who receive a clinical diagnosis of another developmental or psychiatric disorder
Healthy ControlsIndividuals who have no specific developmental or psychiatric diagnosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of correctly discriminated ASD and non-ASD cases using the autism risk index.

    In the development phase, all of the eye gaze measurements acquired from the social attention paradigm will be included as predictor variables in a random forest analysis. This analysis permits evaluation of the discriminative ability of a large number of variables in data sets with a modest number of cases. The variables with highest importance scores, indicating good diagnostic discrimination, will be entered into a logistic regression analysis with ASD diagnostic status (ASD vs. non-ASD) as the dichotomous dependent variable. Significant predictors will be retained and coefficients from the retained predictors will serve as the diagnostic autism risk index.

    Measured: 1 year from study start

Secondary outcomes (21)
  1. Area under the ROC curve of the prognostic algorithm in discriminating non-verbal cognitive disability.

    All the available eye tracking measurements as predictors and non-verbal cognitive ability scores (dichotomized at <70 and 70 and above) as the dependent variable in random forest analyses.

    Measured: 21 months from study start

  2. Number of regions of interest with significant dwell time differences between ASD-affected and non-ASD participants.

    Effect size between ASD and non-ASD participants for dwell time relative to social targets presented in the social attention paradigm.

    Measured: 3 months from study start

  3. Natural Interaction, Monologue with Directed Attention Stimulus - Dwell time in Upper Face Region of Interest (ROI) from 0.5-24 seconds

    Measured: 6 months from study start

  4. Natural Interaction, Monologue with Directed Attention Stimulus - Dwell time in Desk picture and Cup/Phone Regions of Interest (ROI) from 0.5-24 seconds

    Measured: 6 months from study start

  5. Natural Interaction, Joke 1 Stimulus - Dwell time in the Upper and Lower Face ROIs from 0.5-5.5 seconds

    Measured: 6 months from study start

  6. Natural Interaction, Joke 1 Stimulus - Dwell time in Body and Toys ROIs from 0.5-6.88 seconds

    Measured: 6 months from study start

  7. Natural Interaction, Joke 2 Stimulus - Dwell time in Upper Face ROI and Lower Face ROI from 0.5-8.0 seconds

    Measured: 6 months from study start

  8. Natural Interaction, Joke 2 Stimulus - Dwell time in Upper Face ROI from 4.3-5.0 seconds

    Measured: 6 months from study start

  9. Natural Interaction, Joke 2 Stimulus - Dwell time in Distractor 1, Distractor 2, Distractor 3 and Body ROIs from 0.2-10.34 seconds

    Measured: 6 months from study start

  10. Joint Attention, Gaze Middle Stimulus - Dwell time in Face ROI from 0.3-1.1 seconds

    Measured: 6 months from study start

  11. Joint Attention, Gaze Middle Stimulus - Dwell time in Target Toy, Distractor Right and Distractor Left ROIs from 1.0-2.3 seconds

    Measured: 6 months from study start

  12. Joint Attention, Gaze Right Stimulus - Dwell time in Face A and Face B ROIs from 3.3-3.7 seconds

    Measured: 6 months from study start

  13. Joint Attention, Gaze Right Stimulus - Dwell time in Target Toy and Distractor Toy ROIs from 1.0-2.3 seconds

    Measured: 6 months from study start

  14. Joint Attention, Gaze Right 2 Stimulus - Dwell time in Face ROI from 2.0-3.0

    Measured: 6 months from study start

  15. Joint Attention, Gaze Right 2 Stimulus - Dwell time in Left Distractor, Middle Distractor and Right Target from 0.9-1.6 seconds

    Measured: 6 months from study start

  16. Joint Attention, Gesture Middle 1 Stimulus - Left Distractor, Right Distractor and Middle Target from 1.5-3.5 seconds

    Measured: 6 months from study start

  17. Joint Attention, Gesture Right 1 Stimulus - Target Toy, Distractor Middle and Distractor Left ROIs from 0.8-3.5 seconds

    Measured: 6 months from study start

  18. Joint Attention, Gesture Right 2 Stimulus - Target Toy and Distractor Toy ROIs from 1.3-2.4 seconds

    Measured: 6 months from study start

  19. Joint Attention, Gesture Left 1 Stimulus - Target Toy, Distractor Middle and Distractor Right ROIs from 1.4-3.4 seconds

    Measured: 6 months from study start

  20. Joint Attention, Gesture Left 2 Stimulus - Target Toy and Distractor Right ROIs from 1.2-2.7 seconds

    Measured: 6 months from study start

  21. Joint Attention - Gesture Left 3 Stimulus - Left Target, Middle Distractor and Right Distractor ROIs from 0.7-2.3 seconds

    Measured: 6 months from study start

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2015 (estimated)
  2. Study startJun 2015
  3. Primary completionDec 2016
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
389 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02573428
Sponsor's protocol ID
14-620
Acronym
EYE
Status last verified
Mar 2017
First submitted
7 Oct 2015
Last updated
14 Mar 2017
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Publications

  • Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, McMahon WM, Petersen PB, Mo A, Ritvo A. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry. 1989 Feb;146(2):194-9. doi: 10.1176/ajp.146.2.194.

    PubMed 2783539
  • Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry. 2005;66 Suppl 10:3-8.

    PubMed 16401144
  • Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014 Mar 28;63(2):1-21.

    PubMed 24670961
  • Ganz ML. The costs of autism. In: Moldin SO, Rubenstein JLR, eds. Understanding autism: From basic neuroscience to treatment: CRC Press; 2006.

  • Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med. 2007 Apr;161(4):343-9. doi: 10.1001/archpedi.161.4.343.

    PubMed 17404130
  • Pierce K, Carter C, Weinfeld M, Desmond J, Hazin R, Bjork R, Gallagher N. Detecting, studying, and treating autism early: the one-year well-baby check-up approach. J Pediatr. 2011 Sep;159(3):458-465.e1-6. doi: 10.1016/j.jpeds.2011.02.036. Epub 2011 Apr 27.

    PubMed 21524759
  • Ozonoff S, Iosif AM, Baguio F, Cook IC, Hill MM, Hutman T, Rogers SJ, Rozga A, Sangha S, Sigman M, Steinfeld MB, Young GS. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010 Mar;49(3):256-66.e1-2.

    PubMed 20410715
  • Grice SJ, Halit H, Farroni T, Baron-Cohen S, Bolton P, Johnson MH. Neural correlates of eye-gaze detection in young children with autism. Cortex. 2005 Jun;41(3):342-53. doi: 10.1016/s0010-9452(08)70271-5.

    PubMed 15871599
  • Lord, RM, DiLavore PC, et al. Autism Diagnostic Observation Schedule: WPS (ADOS-WPS). Los Angeles, CA: Western Psychological Services. 1999.

  • Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A. Autism and pervasive developmental disorders. J Child Psychol Psychiatry. 2004 Jan;45(1):135-70. doi: 10.1046/j.0021-9630.2003.00317.x.

    PubMed 14959806
  • Bolton PF, Golding J, Emond A, Steer CD. Autism spectrum disorder and autistic traits in the Avon Longitudinal Study of Parents and Children: precursors and early signs. J Am Acad Child Adolesc Psychiatry. 2012 Mar;51(3):249-260.e25. doi: 10.1016/j.jaac.2011.12.009. Epub 2012 Feb 3.

    PubMed 22365461
  • Kozlowski AM, Matson JL, Horovitz M, Worley JA, Neal D. Parents' first concerns of their child's development in toddlers with autism spectrum disorders. Dev Neurorehabil. 2011;14(2):72-8. doi: 10.3109/17518423.2010.539193.

    PubMed 21410398
  • Jones W, Klin A. Attention to eyes is present but in decline in 2-6-month-old infants later diagnosed with autism. Nature. 2013 Dec 19;504(7480):427-31. doi: 10.1038/nature12715. Epub 2013 Nov 6.

    PubMed 24196715
  • Chawarska K, Macari S, Shic F. Decreased spontaneous attention to social scenes in 6-month-old infants later diagnosed with autism spectrum disorders. Biol Psychiatry. 2013 Aug 1;74(3):195-203. doi: 10.1016/j.biopsych.2012.11.022. Epub 2013 Jan 11.

    PubMed 23313640
  • Wolff JJ, Gu H, Gerig G, Elison JT, Styner M, Gouttard S, Botteron KN, Dager SR, Dawson G, Estes AM, Evans AC, Hazlett HC, Kostopoulos P, McKinstry RC, Paterson SJ, Schultz RT, Zwaigenbaum L, Piven J; IBIS Network. Differences in white matter fiber tract development present from 6 to 24 months in infants with autism. Am J Psychiatry. 2012 Jun;169(6):589-600. doi: 10.1176/appi.ajp.2011.11091447.

    PubMed 22362397

Questions about this trial

What is this clinical trial studying?

An observational study of Autism Spectrum Disorders, run by The Cleveland Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of correctly discriminated ASD and non-ASD cases using the autism risk index. (time frame: 1 year from study start). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02573428, which also lists 21 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in